Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation reports recurring developments as a commercial-stage biopharmaceutical company focused on hematologic malignancies. Its first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
Company updates commonly cover RYTELO net product revenue, U.S. commercialization, financial results and guidance, and continued development of imetelstat in JAK-inhibitor relapsed or refractory myelofibrosis and other hematologic malignancies. Geron news also includes investor conference participation, Nasdaq inducement grants, board appointments, executive leadership changes, and restructuring-related business updates.
Geron (Nasdaq: GERN) has announced its upcoming participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management team will engage in a fireside chat at the event, scheduled for December 4, 2024, at 8:20 a.m. ET in Coral Gables, Florida. A webcast of the presentation will be accessible through the Investors and Media section of Geron's website under Events and will remain available for replay for 30 days following the event.
Geron (Nasdaq: GERN) announced the granting of non-statutory stock options to newly hired employees. The company granted options to purchase 1,017,000 shares of common stock at an exercise price of $3.99 per share, matching the closing price on November 20, 2024. The options have a 10-year term and vest over four years, with 12.5% vesting after six months and the remainder vesting over 42 months in equal installments. These grants were made as employment inducements under Nasdaq Listing Rule 5635(c)(4) and are subject to Geron's 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) has appointed Joseph Eid, M.D. as Executive Vice President, Research and Development, effective November 11, 2024. Dr. Eid brings over two decades of experience in medical affairs and clinical development, having previously served at Dragonfly Therapeutics and Luzsana Bio. He will lead Geron's R&D organization, overseeing medical, clinical, and safety teams to support RYTELO™ commercially. As part of his employment agreement, Dr. Eid received a stock option grant for 2,500,000 shares at $4.12 per share, vesting over four years.
Geron (Nasdaq: GERN) announced its management team will participate in a fireside chat at the Stifel 2024 Healthcare Conference in New York City. The presentation is scheduled for Monday, November 18th, 2024, at 1:50pm ET.
The company will make a webcast of the fireside chat accessible through the Investors and Media section of Geron's website under Events. The webcast recording will remain available for replay for 30 days following the presentation.
Geron (GERN) has secured up to $375 million in financing through agreements with Royalty Pharma and Pharmakon Advisors. The deal includes $250 million received at closing and access to an additional $125 million in debt. The funding comprises a $125 million synthetic royalty agreement with Royalty Pharma and $250 million in senior secured debt from Pharmakon Advisors. The financing will support RYTELO's commercial launch in the U.S., potential EU launch, Phase 3 IMpactMF trial in myelofibrosis, and supply chain investments.
Geron (GERN) reported Q3 2024 financial results, achieving $28.2 million in RYTELO™ net product revenue in its first full quarter of sales. The company secured $250 million in financing through agreements with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt. Q3 net loss was $26.4 million, or $0.04 per share. Total operating expenses were $56.5 million. The company expects 2024 total operating expenses between $260-270 million. Cash position as of September 30, 2024, was $378.9 million, with pro forma cash of $542.4 million including recent financing proceeds.
Geron (GERN) announced new data presentations for RYTELO™ (imetelstat) at the upcoming ASH Annual Meeting. Key highlights include analyses from the IMerge clinical trial showing imetelstat's clinical activity in lower-risk MDS patients with transfusion-dependent anemia, regardless of prior therapy. Early safety results from the Phase 1 IMproveMF study suggest potential tolerability of imetelstat combined with ruxolitinib in frontline myelofibrosis patients. The data will be presented through six abstracts at the 66th ASH Annual Meeting in December 2024.
Notable results include RBC-transfusion independence rates and hemoglobin improvements across different patient subgroups, with positive responses seen even in patients who received prior treatments like luspatercept, lenalidomide, and HMAs.
Geron (Nasdaq: GERN), a commercial stage biopharmaceutical company, has announced the granting of non-statutory stock options to newly hired employees. The grants, made on October 16, 2024, include options to purchase a total of 680,220 shares of Geron common stock at an exercise price of $4.17 per share, matching the closing price on the grant date.
These stock options have a 10-year term and vest over four years, with 12.5% vesting after six months of employment and the remainder vesting in equal installments over the following 42 months. The grants were made as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms of Geron's 2018 Inducement Award Plan.
Geron (Nasdaq: GERN), a commercial-stage biopharmaceutical company, has announced that it will release its third quarter 2024 financial results and business highlights on Thursday, November 7, 2024. The information will be made available via press release before the market opens and can be accessed on the company's website at www.geron.com/investors.
Additionally, Geron will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the financial results and business highlights. Interested parties can access the webcast by registering online at https://events.q4inc.com/attendee/539655875. The webcast and related presentation will be available on the company's website, with an archive accessible for 30 days following the event.
Geron (Nasdaq: GERN), a commercial stage biopharmaceutical company, has granted non-statutory stock options to newly hired employees as inducements for joining the company. The details are as follows:
- 500,220 shares of Geron common stock options granted
- Grant date: September 18, 2024
- Exercise price: $4.52 per share (equal to closing price on grant date)
- 10-year term
- Vesting schedule: 12.5% after six months, remaining over 42 months in equal installments
These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to Geron's 2018 Inducement Award Plan.